About Paul Kleutghen

Articles by Paul Kleutghen

Treating Primary Plasma Cell Leukemia
Jan 09, 2024
Using KRd Regimen to Treat Plasma Cell Leukemia
Nov 30, 2023
Diabetes and Multiple Myeloma: Not a Great Combination
Nov 09, 2023
A New Potential Triplet for Myeloma Treatment
Oct 24, 2023
Potential Outpatient CAR-T Treatment for Multiple Myeloma
Oct 02, 2023
LAS MÚLTIPLES MANIFESTACIONES DE LA GMSI
Sep 18, 2023
El Impacto de la Dieta en la Enfermedad Residual Mínima Negativa en el Mieloma Múltiple
Sep 06, 2023
A Delicate Topic: Who Gets CAR-T?
Aug 31, 2023
Young Myeloma Patients: A Forgotten Subgroup?
Jul 26, 2023
Why are African Americans Underrepresented in Myeloma Clinical Trials?
Jul 20, 2023
FDA Fast-Track and Orphan Drug Designation for Myeloma Drug Inobrodib
Jul 11, 2023
ASCO 2023: Benefits of Exercise for Multiple Myeloma Patients
Jun 05, 2023
Producción de células CAR-T dentro del cuerpo
May 11, 2023
¿Quién responde mejor a los anticuerpos biespecíficos BCMA contra el mieloma múltiple?
May 03, 2023
Treating Multiple Myeloma by Exploding Cancerous Cells
Apr 17, 2023
The Impact of Diet on MRD-Negativity in Multiple Myeloma
Nov 24, 2022
The Many Different Manifestations of MGUS
Nov 16, 2022
Redefining the Diagnosis for Plasma Cell Leukemia?
Nov 09, 2022
¿Qué ocurre con el transplante autólogo de células madre en los pacientes de edad avanzada con mieloma múltiple?
Oct 26, 2022
Carvykti: Solving Capacity Issues?
Oct 25, 2022
Producing CAR-T Cells Inside the Body
Sep 16, 2022
FDA Grants Breakthrough Therapy Designation to Talquetamab for Multiple Myeloma
Aug 09, 2022
COVID Vaccines, Boosting and Evusheld in Myeloma Patients
Jul 18, 2022
Gracell Biotechnologies: Surmounting CAR-T Myeloma Challenges?
Jun 27, 2022